[Asia Economy Reporter Chunhee Lee] Genome & Company, a microbiome specialist company, announced on the 11th that the results of an anti-obesity microbiome study conducted by multiple research teams, including the research team led by Hansoo Park, CEO of Genome & Company, have been published in Microbiome (IF = 16.837), a top-tier journal in the related field.
The research team analyzed the gut microbiota of 99 healthy Koreans and identified anti-obesity strains by confirming that normal individuals had a significant distribution of anti-obesity strains such as Bifidobacterium bifidum and Bifidobacterium longum compared to obese individuals.
When these strains were administered to obese mouse models and germ-free mouse models respectively, it was confirmed that administration of the anti-obesity strains resulted in weight loss effects and was not influenced by other strains. Additionally, through multi-omics analysis, it was found that even within the same species, the anti-obesity effect varies depending on the strain, and based on this, the mode of action (MOA) of the microbiome's anti-obesity effect was elucidated.
Hansoo Park, CEO of Genome & Company, said, “We are pleased to have elucidated the mode of action of specific microbiomes in the human body through this research. We will continue to strive to further clarify the mechanisms of action.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
